CN1033948C - 二氢螺旋烯酮在制备药物组合物中的应用 - Google Patents

二氢螺旋烯酮在制备药物组合物中的应用 Download PDF

Info

Publication number
CN1033948C
CN1033948C CN90103713A CN90103713A CN1033948C CN 1033948 C CN1033948 C CN 1033948C CN 90103713 A CN90103713 A CN 90103713A CN 90103713 A CN90103713 A CN 90103713A CN 1033948 C CN1033948 C CN 1033948C
Authority
CN
China
Prior art keywords
application
pharmaceutical composition
formula
estrogen
dihydrospiroenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN90103713A
Other languages
English (en)
Chinese (zh)
Other versions
CN1047299A (zh
Inventor
西比尔·贝耶
沃尔特·埃尔格
西野幸重
鲁道夫·韦卓特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6380839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1033948(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1047299A publication Critical patent/CN1047299A/zh
Application granted granted Critical
Publication of CN1033948C publication Critical patent/CN1033948C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN90103713A 1989-05-16 1990-05-16 二氢螺旋烯酮在制备药物组合物中的应用 Expired - Lifetime CN1033948C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3916112A DE3916112A1 (de) 1989-05-16 1989-05-16 Dihydrospirorenon als antiandrogen
DEP3916112.9 1989-05-16

Publications (2)

Publication Number Publication Date
CN1047299A CN1047299A (zh) 1990-11-28
CN1033948C true CN1033948C (zh) 1997-02-05

Family

ID=6380839

Family Applications (1)

Application Number Title Priority Date Filing Date
CN90103713A Expired - Lifetime CN1033948C (zh) 1989-05-16 1990-05-16 二氢螺旋烯酮在制备药物组合物中的应用

Country Status (20)

Country Link
US (1) US5569652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0398460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2848919B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1033948C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE154881T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU642876B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR1101055A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2016780C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD294417A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE3916112A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0398460T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2106728T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3024861T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU213408B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE81143B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL94416A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91065I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300221I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT94038B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA903754B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321957C2 (de) * 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Verwendung eines hormonalen Mittels zur Therapie der Akne
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
MEP36008A (hr) 1999-08-31 2011-02-10 Bayer Schering Pharma Ag Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1353699B1 (en) * 2000-12-20 2012-02-01 Bayer Pharma Aktiengesellschaft Beta-cyclodextrin-drospirenone inclusion complexes
AU2003222010A1 (en) * 2002-03-18 2003-10-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
WO2003080068A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
WO2004070048A1 (en) * 2003-02-07 2004-08-19 Pharmacia & Upjohn Company Llc A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
NZ549792A (en) 2004-03-10 2009-12-24 Bayer Schering Pharma Ag Compositions comprising drospirenone molecularly dispersed
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
ITMI20042338A1 (it) * 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US8475838B2 (en) * 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
EP1746101B2 (de) * 2005-07-21 2014-05-14 Bayer Pharma Aktiengesellschaft Verfahren zur Herstellung von 3-Oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie Oxidation von 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanen
US7319154B2 (en) 2005-07-21 2008-01-15 Bayer Schering Pharma Ag Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
CA2725578A1 (en) * 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
US4347245A (en) * 1981-05-26 1982-08-31 German Shapiro Spironolactone-containing composition and use thereof
JPS59139400A (ja) * 1983-01-31 1984-08-10 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4855289A (en) * 1984-06-04 1989-08-08 Wester Per O Combination of two active substances
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3615376A1 (de) * 1986-05-07 1987-11-12 Schering Ag 2,2;6,6-diethylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women

Also Published As

Publication number Publication date
DE122004000006I1 (de) 2006-06-08
CN1047299A (zh) 1990-11-28
IL94416A0 (en) 1991-03-10
GR3024861T3 (en) 1998-01-30
HU213408B (en) 1997-06-30
JP2848919B2 (ja) 1999-01-20
PT94038A (pt) 1991-01-08
IL94416A (en) 1997-07-13
ATE154881T1 (de) 1997-07-15
EP0398460A3 (de) 1991-09-25
DE3916112A1 (de) 1990-11-22
DE59010730D1 (de) 1997-08-07
CA2016780A1 (en) 1990-11-16
AU5509490A (en) 1990-11-22
DE3916112C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-30
BR1101055A (pt) 2000-08-08
EP0398460B1 (de) 1997-07-02
NL300221I1 (nl) 2006-04-03
DD294417A5 (de) 1991-10-02
ZA903754B (en) 1991-02-27
DK0398460T3 (da) 1998-02-16
IE901738L (en) 1990-11-16
NL300221I2 (nl) 2006-11-01
LU91065I2 (fr) 2004-03-30
JPH0395121A (ja) 1991-04-19
ES2106728T3 (es) 1997-11-16
PT94038B (pt) 1997-06-30
CA2016780C (en) 2000-07-11
US5569652A (en) 1996-10-29
HUT54500A (en) 1991-03-28
IE81143B1 (en) 2000-04-19
HU903045D0 (en) 1990-09-28
EP0398460A2 (de) 1990-11-22
AU642876B2 (en) 1993-11-04

Similar Documents

Publication Publication Date Title
CN1033948C (zh) 二氢螺旋烯酮在制备药物组合物中的应用
KR100186780B1 (ko) 피임제제
KR100369206B1 (ko) 에스트로겐및게스타겐함유피임용조성물
CA2609336C (en) Quadraphasic continuous graduated estrogen contraceptive
EP0835114B1 (de) Pharmazeutisches kombinationspräparat, kit und methode zur hormonalen kontrazeption
JP6134491B2 (ja) 延長されたホルモン避妊法における破綻出血の管理
RU2001129160A (ru) Прерывистая гормонозаместительная терапия низкими дозами эстрогена
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
DE69729956T2 (de) Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
CZ290697B6 (cs) Systém pro perorální antikoncepci
CN1077430C (zh) 激素避孕法的药物复合制剂
JP2942560B2 (ja) エストロゲン欠乏症治療用組成物
CN1281363A (zh) 孕激素-抗孕激素体系
AU2011226911B2 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
HK1246664A1 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
CZ289697A3 (en) Injection administered once a month as a depot contraception and for hormonal substitution therapy for women in perimenstrual and premenstrual pause
ZA200609988B (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
MXPA01010976A (es) Uso de antiprogestagenos en terapia combinada.
CN1223585A (zh) 孕激素－抗－孕激素药物方案
HK1186108A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
ASS Succession or assignment of patent right

Owner name: BAYER SCHERING PHARMA AG

Free format text: FORMER OWNER: SCHERING CORP.

Effective date: 20091127

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091127

Address after: Berlin

Patentee after: Bayer Schering Pharma AG

Address before: Berlin, Federal Republic of Germany

Patentee before: SCHERING CORP (US)

C17 Cessation of patent right
CX01 Expiry of patent term

Granted publication date: 19970205